AstraZeneca reported robust Q3 2024 results, with total revenue up 21% at CER to $13.6 billion and core EPS rising 27% to $2.08. The company upgraded its full-year 2024 guidance, now expecting high teens percentage growth for both total revenue and core EPS at CER.Product sales grew 20% at CER, driven by strong performance across Oncology (+22%), CVRM (+20%), and R&I (+29%). Key growth drivers included Tagrisso, Imfinzi, Farxiga, and Ultomiris. The company highlighted positive data readouts and regulatory approvals for several medicines, including Tagrisso, Imfinzi, and Enhertu.AstraZeneca noted it is taking the matters in China very seriously and will fully cooperate with authorities if requested. The company remains committed to delivering innovative medicines to patients in China. CEO Pascal Soriot expressed confidence in the company's growth trajectory through 2025 and its ability to deliver on its 2030 ambition.

AstraZeneca reported robust Q3 2024 results, with total revenue up 21% at CER to $13.6 billion and core EPS rising 27% to $2.08. The company upgraded its full-year 2024 guidance, now expecting high teens percentage growth for both total revenue and core EPS at CER.Product sales grew 20% at CER, driven by strong performance across Oncology (+22%), CVRM (+20%), and R&I (+29%). Key growth drivers included Tagrisso, Imfinzi, Farxiga, and Ultomiris. The company highlighted positive data readouts and regulatory approvals for several medicines, including Tagrisso, Imfinzi, and Enhertu.AstraZeneca noted it is taking the matters in China very seriously and will fully cooperate with authorities if requested. The company remains committed to delivering innovative medicines to patients in China. CEO Pascal Soriot expressed confidence in the company's growth trajectory through 2025 and its ability to deliver on its 2030 ambition.